Cross-Sectional Analyses to Assess the Clinical Safety and Effectiveness of Bisoprolol in Patients With Non-obstructive Coronary Artery Disease Who Underwent Percutaneous Coronary Intervention: A Post-hoc Analysis
Bisoprolol remains a clinically feasible option in Indian patients with NOCAD cases following percutaneous coronary intervention (PCI) as it reduces RHR and improves LVEF. Despite high rates of cardiovascular risk factors like age, type 2 diabetes and diffuse polyvascular disease, the drug was well-tolerated, with fewer adverse events. These results support the use of bisoprolol in managing NOCAD in Indian patients, highlighting its potential therapeutic uses to prevent further cardiac dysfunction.
Authors
- Brian Pinto
- Arup Deb (ORCID: https://orcid.org/0000-0002-0775-824X)
- Rathish Nair (ORCID: https://orcid.org/0000-0002-8786-9416)
- Girish Kulkarni
- Krishnaprasad R Korukonda
- Soumitra Kumar (ORCID: https://orcid.org/0000-0001-8999-6761)
- Amit Khandelwal (ORCID: https://orcid.org/0009-0000-8102-3535)
- Louie Fischer (ORCID: https://orcid.org/0009-0005-5672-1135)
Institutions
- National Institute of Technology Agartala (IN)
- Malankara Orthodox Syrian Church Medical College Hospital (IN)
- Art Research Centre of the Slovak Academy of Sciences (SK)
- Pain Clinic of India (IN)
- Bombay Hospital (IN)
- Torrent Pharma (India) (IN)
Publication Details
- Journal
- Cureus
- Published
- 2024-12-03
- DOI
- https://doi.org/10.7759/cureus.75021
- Primary Topic
- Heart rate and cardiovascular health
- Type
- article
- Field-Weighted Citation Impact
- 0.00